EYPT EyePoint Pharmaceuticals Inc

Price (delayed)

$3.72

Market cap

$320.71M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.75

Enterprise value

$229.92M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 8

EyePoint Pharmaceuticals is a pharmaceutical company committed to developing and commercializing therapeutics to help improve the lives of patients with serious eye disorders. The Company's pipeline leverages its proprietary Durasert ...

Highlights
The debt has declined by 9% year-on-year and by 2.1% since the previous quarter
EYPT's gross profit has dropped by 98% year-on-year and by 80% since the previous quarter
The revenue has dropped by 95% year-on-year and by 63% since the previous quarter

Key stats

What are the main financial stats of EYPT

EYPT stock price

How has the EyePoint Pharmaceuticals stock price performed over time
Intraday
-8.6%
1 week
7.83%
1 month
-30.08%
1 year
-72.22%
YTD
-79.64%
QTD
-73.99%

Financial performance

How have EyePoint Pharmaceuticals's revenue and profit performed over time
Revenue
$2.79M
Gross profit
$1.17M
Operating income
-$316.98M
Net income
-$306.64M
Gross margin
41.8%
Net margin
-10,994.7%
EYPT's gross profit has dropped by 98% year-on-year and by 80% since the previous quarter
The revenue has dropped by 95% year-on-year and by 63% since the previous quarter
The net income has dropped by 75% year-on-year and by 13% since the previous quarter
The operating income has plunged by 68% YoY and by 12% from the previous quarter

Price vs fundamentals

How does EYPT's price correlate with its fundamentals

Growth

What is EyePoint Pharmaceuticals's growth rate over time

Valuation

What is EyePoint Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.87
P/S
115.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
82.44
The EPS has contracted by 39% YoY and by 7% from the previous quarter
The stock's price to book (P/B) is 62% less than its last 4 quarters average of 5.4 and 34% less than its 5-year quarterly average of 3.1
EYPT's equity is down by 32% year-on-year and by 28% since the previous quarter
The revenue has dropped by 95% year-on-year and by 63% since the previous quarter
EYPT's P/S is 23% below its last 4 quarters average of 163.9

Efficiency

How efficient is EyePoint Pharmaceuticals business performance
The ROIC has shrunk by 139% YoY and by 33% QoQ
EYPT's return on assets has dropped by 114% year-on-year and by 20% since the previous quarter
EyePoint Pharmaceuticals's ROE has plunged by 113% YoY and by 23% from the previous quarter

Dividends

What is EYPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EYPT.

Financial health

How did EyePoint Pharmaceuticals financials performed over time
EYPT's quick ratio is down by 44% year-on-year and by 28% since the previous quarter
EyePoint Pharmaceuticals's current ratio has decreased by 44% YoY and by 32% from the previous quarter
The debt is 88% smaller than the equity
EYPT's debt to equity is up by 33% since the previous quarter and by 33% year-on-year
EYPT's equity is down by 32% year-on-year and by 28% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.